Accolade (ACCD)
(Delayed Data from NSDQ)
$7.89 USD
-1.30 (-14.15%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $7.89 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
ACCD 7.89 -1.30(-14.15%)
Will ACCD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ACCD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACCD
Accolade (ACCD) Reports Q4 Loss, Tops Revenue Estimates
Strength Seen in Paymentus (PAY): Can Its 7.8% Jump Turn into More Strength?
ACCD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Business Services Stocks Lagging Accolade (ACCD) This Year?
Does Accolade (ACCD) Have the Potential to Rally 25.58% as Wall Street Analysts Expect?
Zacks.com featured highlights include AxoGen, Western Digital, Accolade and Credo Technology Group
Other News for ACCD
Accolade, Inc. at a Crossroads: Navigating Regulatory Risks in AI Integration
12 Health Care Stocks Moving In Friday's Intraday Session
Accolade price target lowered by $4 at Needham, here's why
Analysts Are Bullish on These Healthcare Stocks: Accolade (ACCD), PROCEPT BioRobotics (PRCT)
Accolade price target lowered by $2 at Canaccord, here's why